Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis
Mohamed Elsaid, Veterinary Surgeon at Canadian Veterinary Hospital, shared on LinkedIn:
”Hyperlipidemia in Cushing’s Syndrome and Its Role in Thrombogenesis
Hyperlipidemia is a common but often underestimated metabolic consequence of Cushing’s syndrome, and it plays a direct role in the development of thromboembolic disease.
Pathophysiology
Chronic hypercortisolism induces dyslipidemia through multiple mechanisms:
- Increased hepatic VLDL synthesis
- Enhanced lipolysis with redistribution of free fatty acids
- Reduced activity of lipoprotein lipase
- Insulin resistance contributing to altered lipid metabolism
This typically results in:
– Marked hypertriglyceridemia
– Elevated total cholesterol
– Lipemic or grossly turbid serum samples (as seen clinically)
– Link Between Hyperlipidemia and Thrombosis
Hyperlipidemia contributes to thrombogenesis by:
- Increasing blood viscosity
- Promoting endothelial dysfunction
- Enhancing platelet activation and aggregation
- Reducing fibrinolytic activity via increased PAI-1
- Upregulating procoagulant factors (Factors VIII, IX, XI)
These effects act synergistically with cortisol-induced:
Antithrombin III suppression
Decreased protein C and S activity
The result is a profound hypercoagulable state.
Clinical Implications
Patients with Cushing’s syndrome are predisposed to:
Venous thromboembolism (VTE)
Pulmonary thromboembolism
Microthrombi affecting renal, hepatic, and pulmonary perfusion
Hyperlipidemia should therefore be viewed as a pathologic contributor, not merely a biochemical abnormality.
Clinical Take-Home Messages
– Lipemic serum in Cushing’s patients is a red flag
– Routine lipid profiling should be part of endocrine case monitoring
– Thrombotic risk assessment is essential, especially in severe or untreated cases
– Early intervention may reduce morbidity and mortality.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers